Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480771 | 0.98 | NPSR1 (0.46) | NPSR1MAOAMAOBALDH1A1SMN1; SMN2 | |
| SCHEMBL6489116 | 0.96 | HSD17B10 (0.44) | NPSR1MAOAMAOBSMN1; SMN2HSD17B10 | |
| SCHEMBL6492402 | 0.94 | NPSR1 (0.46) | NPSR1MAOAMAOBALDH1A1SMN1; SMN2 | |
| SCHEMBL6492666 | 0.93 | NPSR1 (0.45) | NPSR1MAOAMAOBALDH1A1SMN1; SMN2 | |
| SCHEMBL6489974 | 0.92 | JAK2 (0.43) | NPSR1MAOAMAOBSMN1; SMN2HSD17B10 | |
| SCHEMBL6480678 | 0.92 | ACKR3 (0.44) | NPSR1MAOAMAOBALDH1A1SMN1; SMN2 | |
| SCHEMBL6492171 | 0.91 | ACKR3 (0.46) | NPSR1MAOAMAOBALDH1A1LMNA | |
| SCHEMBL6490688 | 0.90 | MGLL (0.44) | MAOBSMN1; SMN2HSD17B10LMNAHPGD | |
| SCHEMBL6480480 | 0.90 | RORC (0.43) | NPSR1MAOAMAOBALDH1A1HSD17B10 | |
| SCHEMBL6480181 | 0.89 | NPSR1 (0.51) | NPSR1MAOAMAOBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215614-A1 | Substituted indoles and their use as hcv inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | US | claimed |
| US-20050215614-A1 | Substituted indoles and their use as hcv inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215614-A1 | Substituted indoles and their use as hcv inhibitors | IDO1, IDO2, HAVCR2 | NPSR1 556/4885MAOA 28/4885MAOB 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.